Precigen reported $53.1 million in net revenue from PAPZIMEOS in Q2 2026, more than doubling the previous quarter and leading to the company's first quarterly profitability. PAPZIMEOS, an FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), has seen broad adoption with over 500 patients enrolled across the US and nearly full payer coverage. The FDA granted PAPZIMEOS seven years of market exclusivity, securing its competitive position. Precigen expects continued growth, aiming for cash flow break-even by year-end 2026, and plans to expand PAPZIMEOS globally and into pediatric use while advancing related therapies in HPV-associated cancers.
PetroChina reported a 22% year-over-year increase in net income for the first half of 2026, driven by strong performance in its upstream and natural gas segments due to higher oil prices and cost optimization. The company expects continued profit gro...
The iShares Copper and Metals Mining ETF (ICOP) is rated a Buy amid copper's ongoing multidecade bull market, driven by strong technical and fundamental factors. In 2026, ICOP outperformed copper futures with a 29.3% gain year-to-date, compared to co...
Bitcoin is trading near $77,000-$79,000 amid rising Japanese government bond yields and a strong yen rally. Japan's 10-year bond yield reached 3% for the first time since 1996, pushing borrowing costs higher and triggering concerns over a $500 billio...
Concerns about circular financing in the AI sector are exaggerated, as such practices are common and serve as risk mitigation in mature industries. The AI industry's higher scrutiny is due to its immaturity and concentrated risks, not the novelty of ...
Bitcoin has surged from the low $60,000s to over $80,000, driven by concerns over US fiscal sustainability and Treasury debt. Investors are increasingly viewing Bitcoin as a store of value similar to gold, using it as a hedge against currency debasem...
